drugset
drugset / Trial / NCT02448212

Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects

NCT02448212 ↗

Phase 1 Completed 15 enrolled Taisho Pharmaceutical R&D Inc. Yale University · collab
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the binding of a novel tracer, \[11C\]TASP0410699, using Positron Emission Tomography (PET) scans with or without dosing of TS-121

Timeline

Start
2015-05
Primary completion
2016-01
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BREZIVAPTAN Small molecule — Oral
Subject [11C]TASP0410699 Diagnostic / imaging agent — Intravenous

Indications

No indication recorded.